news
11-16-2023, 03:10 PM
Can TB be eliminated? This year brings progress but obstacles loom : Goats and Soda (https://news.google.com/rss/articles/CBMiiwFodHRwczovL3d3dy5ucHIub3JnL3NlY3Rpb25zL2dvYX RzYW5kc29kYS8yMDIzLzExLzE2LzEyMTEwNjIyMDYvd2hvLXNh eXMtd2UtY2FuLXdyaXRlLXRoZS1maW5hbC1jaGFwdGVyLWluLX RoZS1zdG9yeS1vZi10Yi1ob3ctY2xvc2UtYXJlLXdl0gEA?oc= 5) NPR
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial (https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3LnRoZWxhbmNldC5jb20vam91cm5hbH MvbGFucmVzL2FydGljbGUvUElJUzIyMTMtMjYwMCgyMykwMDM4 OS0yL2Z1bGx0ZXh00gEA?oc=5) The Lancet
Indian drugmaker to supply key component of drug-resistant TB regimens (https://news.google.com/rss/articles/CBMidWh0dHBzOi8vd3d3LmNpZHJhcC51bW4uZWR1L2FudGltaW Nyb2JpYWwtc3Rld2FyZHNoaXAvaW5kaWFuLWRydWdtYWtlci1z dXBwbHkta2V5LWNvbXBvbmVudC1kcnVnLXJlc2lzdGFudC10Yi 1yZWdpbWVuc9IBAA?oc=5) University of Minnesota Twin Cities
Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options (https://news.google.com/rss/articles/CBMiemh0dHBzOi8vd3d3LmRvY3RvcnN3aXRob3V0Ym9yZGVycy 5jYS9sYW5kbWFyay1jbGluaWNhbC10cmlhbC1yZWRlZmluZXMt bXVsdGlkcnVnLXJlc2lzdGFudC10dWJlcmN1bG9zaXMtdHJlYX RtZW50LW9wdGlvbnMv0gEA?oc=5) Doctors Without Borders
View Full Coverage on Google News (https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZjbmt0TXpZd1NoRUtEd2lPbH J2ZUNSRlMwdDBkWE5qX2pTZ0FQAQ?hl=en-US&gl=US&ceid=US:en&oc=5)
More... (https://news.google.com/rss/articles/CBMiiwFodHRwczovL3d3dy5ucHIub3JnL3NlY3Rpb25zL2dvYX RzYW5kc29kYS8yMDIzLzExLzE2LzEyMTEwNjIyMDYvd2hvLXNh eXMtd2UtY2FuLXdyaXRlLXRoZS1maW5hbC1jaGFwdGVyLWluLX RoZS1zdG9yeS1vZi10Yi1ob3ctY2xvc2UtYXJlLXdl0gEA?oc= 5)
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial (https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3LnRoZWxhbmNldC5jb20vam91cm5hbH MvbGFucmVzL2FydGljbGUvUElJUzIyMTMtMjYwMCgyMykwMDM4 OS0yL2Z1bGx0ZXh00gEA?oc=5) The Lancet
Indian drugmaker to supply key component of drug-resistant TB regimens (https://news.google.com/rss/articles/CBMidWh0dHBzOi8vd3d3LmNpZHJhcC51bW4uZWR1L2FudGltaW Nyb2JpYWwtc3Rld2FyZHNoaXAvaW5kaWFuLWRydWdtYWtlci1z dXBwbHkta2V5LWNvbXBvbmVudC1kcnVnLXJlc2lzdGFudC10Yi 1yZWdpbWVuc9IBAA?oc=5) University of Minnesota Twin Cities
Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options (https://news.google.com/rss/articles/CBMiemh0dHBzOi8vd3d3LmRvY3RvcnN3aXRob3V0Ym9yZGVycy 5jYS9sYW5kbWFyay1jbGluaWNhbC10cmlhbC1yZWRlZmluZXMt bXVsdGlkcnVnLXJlc2lzdGFudC10dWJlcmN1bG9zaXMtdHJlYX RtZW50LW9wdGlvbnMv0gEA?oc=5) Doctors Without Borders
View Full Coverage on Google News (https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZjbmt0TXpZd1NoRUtEd2lPbH J2ZUNSRlMwdDBkWE5qX2pTZ0FQAQ?hl=en-US&gl=US&ceid=US:en&oc=5)
More... (https://news.google.com/rss/articles/CBMiiwFodHRwczovL3d3dy5ucHIub3JnL3NlY3Rpb25zL2dvYX RzYW5kc29kYS8yMDIzLzExLzE2LzEyMTEwNjIyMDYvd2hvLXNh eXMtd2UtY2FuLXdyaXRlLXRoZS1maW5hbC1jaGFwdGVyLWluLX RoZS1zdG9yeS1vZi10Yi1ob3ctY2xvc2UtYXJlLXdl0gEA?oc= 5)